Phenanthrene

Phenanthrene

SCHEMBL984028

c1ccc2c(c1)ccc1ccccc12.c1cscn1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.50
ALDH1A1 P00352 2/20 0.50
HSD17B10 Q99714 2/20 0.50
TSHR P16473 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
HPRT1 P00492 3/20 0.46
CYP3A4 P08684 2/20 0.44
HIF1A Q16665 1/20 0.43
CYP1B1 Q16678 1/20 0.43
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
APEX1 P27695 1/20 0.40
MAPK1 P28482 1/20 0.40
PMP22 Q01453 1/20 0.40
PAX8 Q06710 1/20 0.39
F12 P00748 1/20 0.36
PLAU P00749 1/20 0.36
NCF1 P14598 1/20 0.36
NOS3 P29474 1/20 0.36
NOS1 P29475 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Naphthalene SCHEMBL303703 0.87 CYP2A6 (0.40) CYP2A6ALDH1A1
Phenazine SCHEMBL18063602 0.83 MAPT (0.50) ALDH1A1HSD17B10TDP1MAPTNQO2
Anthracene SCHEMBL27585398 0.83 ALDH1A1 (0.37) CYP2A6ALDH1A1HSD17B10TDP1CYP3A4
Hydrochlorthiazide SCHEMBL8852029 0.82 TDP1 (0.35) CYP2A6ALDH1A1HSD17B10TSHRTDP1
Pyrene SCHEMBL17144401 0.81 HSD17B10 (0.48) ALDH1A1HSD17B10TSHRTDP1CYP3A4
Hydrochlorthiazide SCHEMBL2541220 0.81 PLAU (0.41) CYP2A6ALDH1A1HSD17B10TSHRCYP3A4
Naphthalene SCHEMBL3934202 0.79 TSHR (0.38) CYP2A6TSHRTDP1CYP3A4
Dibenzothiophene SCHEMBL27966834 0.78 GPR3 (0.56) ALDH1A1HSD17B10TDP1HIF1AMAPT
Dibenzothiophene SCHEMBL27966651 0.78 GPR3 (0.56) ALDH1A1HSD17B10TDP1HIF1AMAPT
Hydrochlorthiazide SCHEMBL26114764 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2984079-B1 HETEROCYCLIC COMPOUNDS AND THEIR USE IN ELECTRO-OPTICAL OR OPTO-ELECTRONIC DEVICES POWER OLEDS LTD (GB) 2020-07-01 EP disclosed
US-10439147-B2 Heterocyclic compounds and their use in electro-optical or opto-electronic devices POWER OLEDS LIMITED (GB) 2019-10-08 US disclosed
CN-105189475-B Heterocyclic compounds and their use in electro-optical or opto-electronic devices 动力欧勒德斯有限公司 2018-12-21 CN disclosed
US-20180323378-A9 HETEROCYCLIC COMPOUNDS AND THEIR USE IN ELECTRO-OPTICAL OR OPTO-ELECTRONIC DEVICES POWER OLEDS LIMITED (GB) 2018-11-08 US disclosed
CN-108017645-A A kind of perimidine derivative and its application 北京鼎材科技有限公司 2018-05-11 CN disclosed
EP-2232611-B1 BARRIER COATED SUBSTRATE AND ELECTRO-OPTICAL DEVICE MERCK PATENT GMBH (DE) 2017-11-01 EP disclosed
US-9437828-B2 Electroluminescent device using azomethine-lithium-complex as electron injection layer MERCK PATENT GMBH (DE) 2016-09-06 US disclosed
EP-2984079-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE IN ELECTRO-OPTICAL OR OPTO-ELECTRONIC DEVICES Power Oleds Limited (GB) 2016-02-17 EP disclosed
US-20160035983-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE IN ELECTRO-OPTICAL OR OPTO-ELECTRONIC DEVICES POWER OLEDS LTD (GB) 2016-02-04 US disclosed
US-9252383-B2 Cathode coating MERCK PATENT GMBH (DE) 2016-02-02 US disclosed
US-4796971-A CHARGE TRANSFER COMPOUND ON CROSSLINKED MATRIX EASTMAN KODAK COMPANY (US) 1989-01-10 US disclosed
US-4792208-A POLAR ALIGNED NONCENTROSYMMETRIC MOLECULAR DIPOLES; SULFONYL MOIETY AS ELECTRON ACCEPTOR EASTMAN KODAK COMPANY (US) 1988-12-20 US disclosed
EP-0281381-A2 Electroluminescent device with modified thin film luminescent zone EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1988-09-07 EP disclosed
US-4769292-A Electroluminescent device with modified thin film luminescent zone EASTMAN KODAK COMPANY (US) 1988-09-06 US disclosed
EP-0276566-A1 Radiographic element exhibiting reduced crossover EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1988-08-03 EP disclosed
EP-0269398-A2 Enhanced imaging composition containing an azinium activator EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1988-06-01 EP disclosed
EP-0269397-A2 Dye sensitized photographic imaging system EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1988-06-01 EP disclosed
US-4743531-A PHOTORESISTS EASTMAN KODAK COMPANY (US) 1988-05-10 US disclosed
US-4743528-A Enhanced imaging composition containing an azinium activator EASTMAN KODAK COMPANY (US) 1988-05-10 US disclosed
US-4743530-A FILM FORMER, QUATERNIZED AZINIUM SALT ACTIVATOR, PHOTOSENSITIZER DYE EASTMAN KODAK COMPANY (US) 1988-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180323378-A9 HETEROCYCLIC COMPOUNDS AND THEIR USE IN ELECTRO-OPTICAL OR OPTO-ELECTRONIC DEVICES NAT1, SLCO2A1, SLCO2B1 CYP2A6 1385/4885ALDH1A1 789/4885HSD17B10 1935/4885
US-10439147-B2 Heterocyclic compounds and their use in electro-optical or opto-electronic devices NAT1, SLCO2A1, SLCO2B1 CYP2A6 1385/4885ALDH1A1 789/4885HSD17B10 1935/4885
US-20160035983-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE IN ELECTRO-OPTICAL OR OPTO-ELECTRONIC DEVICES NAT1, SLCO2A1, SLCO2B1 CYP2A6 1385/4885ALDH1A1 789/4885HSD17B10 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.